Chemoradiation in advanced vulval carcinoma

Area of Science:

• Gynecologic Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Vulval carcinoma is a rare malignancy, with radical vulvectomy and lymph node dissection as standard treatment.
• Advanced cases may necessitate extensive surgery, including pelvic exenteration, leading to significant morbidity.
• Chemoradiation, successful in anal carcinoma treatment, has been explored as an alternative for advanced vulval cancer.

Purpose of the Study:

• To evaluate the efficacy of chemoradiation as a primary therapy for advanced vulval carcinoma.
• To analyze survival outcomes and identify prognostic factors in patients treated with chemoradiation.

Main Methods:

• Retrospective analysis of medical records from 50 women with advanced vulval carcinoma treated between 1982 and 2001.
• Data included patient demographics, treatment response, surgical intervention, and survival outcomes.
• Statistical analysis to compare survival rates based on treatment response and prognostic factors.

Main Results:

• Complete response to chemoradiation was achieved in 28% of patients, with significantly improved survival compared to partial responders (58%).
• Partial responders who underwent surgery demonstrated significantly better survival rates than those who did not.
• Performance status and tumor stage were identified as significant prognostic factors for survival.

Conclusions:

• Primary chemoradiation offers a less morbid alternative for advanced vulval carcinoma, though complete response rates are below one-third.
• Surgical excision of residual disease in partial responders significantly enhances survival.
• Performance status, age, and tumor stage are critical determinants of survival in this patient population.